[{"id":"a5412ef0-8de3-48a3-beec-bb96a1550b73","acronym":"MOXE","url":"https://clinicaltrials.gov/study/NCT03501615","created_at":"2021-01-18T17:13:55.556Z","updated_at":"2024-07-02T16:36:43.783Z","phase":"","brief_title":"An Early Access Programme for Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia","source_id_and_acronym":"NCT03501615 - MOXE","lead_sponsor":"AstraZeneca","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lumoxiti (moxetumomab pasudotox)"],"overall_status":"Approved for marketing","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2020-06-29"},{"id":"2f7a5d93-470c-4333-bbd7-fc38933e1084","acronym":"PLAIT","url":"https://clinicaltrials.gov/study/NCT01829711","created_at":"2021-01-18T08:08:03.726Z","updated_at":"2024-07-02T16:36:46.386Z","phase":"Phase 3","brief_title":"Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia","source_id_and_acronym":"NCT01829711 - PLAIT","lead_sponsor":"MedImmune LLC","biomarkers":" BRAF • CD22","pipe":"","alterations":" ","tags":["BRAF • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lumoxiti (moxetumomab pasudotox)"],"overall_status":"Completed","enrollment":" Enrollment 80","initiation":"Initiation: 04/29/2013","start_date":" 04/29/2013","primary_txt":" Primary completion: 05/24/2017","primary_completion_date":" 05/24/2017","study_txt":" Completion: 04/29/2019","study_completion_date":" 04/29/2019","last_update_posted":"2020-04-08"},{"id":"bd046914-1a8f-4bf4-839a-b7db634f7c51","acronym":"","url":"https://clinicaltrials.gov/study/NCT00586924","created_at":"2021-01-18T02:09:41.853Z","updated_at":"2024-07-02T16:37:01.009Z","phase":"Phase 1","brief_title":"A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia","source_id_and_acronym":"NCT00586924","lead_sponsor":"MedImmune LLC","biomarkers":" CD22","pipe":" | ","alterations":" CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lumoxiti (moxetumomab pasudotox)"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 05/10/2007","start_date":" 05/10/2007","primary_txt":" Primary completion: 05/06/2015","primary_completion_date":" 05/06/2015","study_txt":" Completion: 05/06/2015","study_completion_date":" 05/06/2015","last_update_posted":"2019-04-02"},{"id":"1a1dde8f-4cf8-4ee4-a9e7-22cc3ac6da9b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01030536","created_at":"2021-01-18T04:02:44.352Z","updated_at":"2024-07-02T16:37:11.654Z","phase":"Phase 1/2","brief_title":"Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL)","source_id_and_acronym":"NCT01030536","lead_sponsor":"MedImmune LLC","biomarkers":" CD22","pipe":" | ","alterations":" CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lumoxiti (moxetumomab pasudotox)"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 02/15/2010","start_date":" 02/15/2010","primary_txt":" Primary completion: 03/04/2013","primary_completion_date":" 03/04/2013","study_txt":" Completion: 03/04/2013","study_completion_date":" 03/04/2013","last_update_posted":"2018-04-09"},{"id":"9aa724b6-3ee9-4fe7-873d-6366f5237f5e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00659425","created_at":"2021-01-18T02:27:28.183Z","updated_at":"2024-07-02T16:37:17.400Z","phase":"Phase 1","brief_title":"CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT00659425","lead_sponsor":"MedImmune LLC","biomarkers":" CD22","pipe":" | ","alterations":" CD22 positive • CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive • CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lumoxiti (moxetumomab pasudotox)"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 09/01/2008","start_date":" 09/01/2008","primary_txt":" Primary completion: 12/01/2014","primary_completion_date":" 12/01/2014","study_txt":" Completion: 12/01/2014","study_completion_date":" 12/01/2014","last_update_posted":"2017-10-02"}]